FR2927539B1 - Procede de preparation d'une formulation pharmaceutique d'agents de contraste. - Google Patents

Procede de preparation d'une formulation pharmaceutique d'agents de contraste.

Info

Publication number
FR2927539B1
FR2927539B1 FR0851055A FR0851055A FR2927539B1 FR 2927539 B1 FR2927539 B1 FR 2927539B1 FR 0851055 A FR0851055 A FR 0851055A FR 0851055 A FR0851055 A FR 0851055A FR 2927539 B1 FR2927539 B1 FR 2927539B1
Authority
FR
France
Prior art keywords
preparing
pharmaceutical formulation
contrast agents
agents
contrast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0851055A
Other languages
English (en)
Other versions
FR2927539A1 (fr
Inventor
Claire Corot
Dominique Meyer
Marc Port
Bruno Bonnemain
Vincent Barbotin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guerbet SA
Original Assignee
Guerbet SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39789784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2927539(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Guerbet SA filed Critical Guerbet SA
Priority to FR0851055A priority Critical patent/FR2927539B1/fr
Priority to US12/155,997 priority patent/US20090208421A1/en
Priority to DE202008010019U priority patent/DE202008010019U1/de
Priority to PL09712403T priority patent/PL2242515T3/pl
Priority to DK09712403.6T priority patent/DK2242515T3/da
Priority to PT141650069T priority patent/PT2799089T/pt
Priority to CN2009801096136A priority patent/CN101977633B/zh
Priority to EP14165008.5A priority patent/EP2799090B2/fr
Priority to HUE14165006A priority patent/HUE030219T2/en
Priority to PCT/EP2009/051937 priority patent/WO2009103744A2/fr
Priority to DK14165006.9T priority patent/DK2799089T3/en
Priority to PT141650085T priority patent/PT2799090T/pt
Priority to JP2010547173A priority patent/JP5469615B2/ja
Priority to EP19204417.0A priority patent/EP3620179A1/fr
Priority to BRPI0908221-2A priority patent/BRPI0908221B1/pt
Priority to LTEP14165008.5T priority patent/LT2799090T/lt
Priority to EP09712403.6A priority patent/EP2242515B9/fr
Priority to PL14165008.5T priority patent/PL2799090T5/pl
Priority to EP16194654.6A priority patent/EP3159014A1/fr
Priority to LTEP14165006.9T priority patent/LT2799089T/lt
Priority to HUE14165008A priority patent/HUE031091T2/en
Priority to US12/918,259 priority patent/US9655983B2/en
Priority to EP14165006.9A priority patent/EP2799089B9/fr
Priority to ES14165008T priority patent/ES2593127T5/es
Priority to DK14165008.5T priority patent/DK2799090T4/da
Priority to EP13154448.8A priority patent/EP2591807A1/fr
Priority to ES14165006.9T priority patent/ES2597782T3/es
Priority to PL14165006T priority patent/PL2799089T3/pl
Priority to CA2714118A priority patent/CA2714118C/fr
Priority to KR1020107020477A priority patent/KR101063060B1/ko
Priority to PT97124036T priority patent/PT2242515E/pt
Priority to ES09712403.6T priority patent/ES2477541T3/es
Publication of FR2927539A1 publication Critical patent/FR2927539A1/fr
Application granted granted Critical
Publication of FR2927539B1 publication Critical patent/FR2927539B1/fr
Priority to US13/971,672 priority patent/US20130336898A1/en
Priority to JP2014015276A priority patent/JP5985523B2/ja
Priority to HRP20140537AT priority patent/HRP20140537T1/hr
Priority to CY20141100489T priority patent/CY1115259T1/el
Priority to JP2016066978A priority patent/JP6422460B2/ja
Priority to US15/140,077 priority patent/US9636427B2/en
Priority to US15/140,132 priority patent/US20160235868A1/en
Priority to HRP20161312TT priority patent/HRP20161312T2/hr
Priority to CY20161101126T priority patent/CY1118985T1/el
Priority to US15/466,600 priority patent/US9907866B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A61K49/105—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA the metal complex being Gd-DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR0851055A 2008-02-19 2008-02-19 Procede de preparation d'une formulation pharmaceutique d'agents de contraste. Expired - Fee Related FR2927539B1 (fr)

Priority Applications (42)

Application Number Priority Date Filing Date Title
FR0851055A FR2927539B1 (fr) 2008-02-19 2008-02-19 Procede de preparation d'une formulation pharmaceutique d'agents de contraste.
US12/155,997 US20090208421A1 (en) 2008-02-19 2008-06-12 Process for preparing a pharmaceutical formulation of contrast agents
DE202008010019U DE202008010019U1 (de) 2008-02-19 2008-07-25 Pharmazeutische Formulierung von Kontrastmitteln
EP14165006.9A EP2799089B9 (fr) 2008-02-19 2009-02-18 Procédé de préparation d'une formulation pharmaceutique d'agents de contraste
DK14165008.5T DK2799090T4 (da) 2008-02-19 2009-02-18 Fremgangsmåde til fremstilling af en farmaceutisk kontrastmiddelformulering
PT141650069T PT2799089T (pt) 2008-02-19 2009-02-18 Processo para produzir uma formulação farmacêutica de agentes de contraste
DK09712403.6T DK2242515T3 (da) 2008-02-19 2009-02-18 Fremgangsmåde til fremstilling af en farmaceutisk kontrastmiddelformulering
EP14165008.5A EP2799090B2 (fr) 2008-02-19 2009-02-18 Procédé de préparation d'une formulation pharmaceutique d'agents de contraste
HUE14165006A HUE030219T2 (en) 2008-02-19 2009-02-18 A method of producing a pharmaceutical composition comprising contrast agents
PCT/EP2009/051937 WO2009103744A2 (fr) 2008-02-19 2009-02-18 Procédé de préparation d’une formulation pharmaceutique d’agents de contraste
DK14165006.9T DK2799089T3 (en) 2008-02-19 2009-02-18 Method of producing a pharmaceutical contrast formulation
PT141650085T PT2799090T (pt) 2008-02-19 2009-02-18 Processo para produzir uma formulação farmacêutica de agentes de contraste
JP2010547173A JP5469615B2 (ja) 2008-02-19 2009-02-18 造影剤の薬学的製剤を調製する方法
ES14165008T ES2593127T5 (es) 2008-02-19 2009-02-18 Proceso para preparar una formulación farmacéutica de agentes de contraste
BRPI0908221-2A BRPI0908221B1 (pt) 2008-02-19 2009-02-18 Processo para preparar uma formulação farmacêutica líquida contendo um complexo de quelate macrocíclico com um lantanídeo
EP13154448.8A EP2591807A1 (fr) 2008-02-19 2009-02-18 Procédé de préparation d'une formulation pharmaceutique d'agents de contraste
EP09712403.6A EP2242515B9 (fr) 2008-02-19 2009-02-18 Procédé de préparation d'une formulation pharmaceutique d'agents de contraste
PL14165008.5T PL2799090T5 (pl) 2008-02-19 2009-02-18 Sposób wytwarzania formulacji farmaceutycznej środków kontrastowych
EP16194654.6A EP3159014A1 (fr) 2008-02-19 2009-02-18 Procédé de préparation d'une formulation pharmaceutique d'agents de contraste
LTEP14165006.9T LT2799089T (lt) 2008-02-19 2009-02-18 Kontrastinio agento farmacinės kompozicijos gamybos būdas
HUE14165008A HUE031091T2 (en) 2008-02-19 2009-02-18 A method for preparing a pharmaceutical composition for a contrast agent
US12/918,259 US9655983B2 (en) 2008-02-19 2009-02-18 Process for preparing a pharmaceutical formulation of contrast agents
PL09712403T PL2242515T3 (pl) 2008-02-19 2009-02-18 Sposób wytwarzania formulacji farmaceutycznej środków kontrastowych
EP19204417.0A EP3620179A1 (fr) 2008-02-19 2009-02-18 Procédé de préparation d'une formulation pharmaceutique d'agents de contraste
CN2009801096136A CN101977633B (zh) 2008-02-19 2009-02-18 用于制备对比剂的药物配制品的方法
LTEP14165008.5T LT2799090T (lt) 2008-02-19 2009-02-18 Kontrastinių agentų farmacinės kompozicijos gamybos būdas
ES14165006.9T ES2597782T3 (es) 2008-02-19 2009-02-18 Proceso para preparar una formulación farmacéutica de agentes de contraste
PL14165006T PL2799089T3 (pl) 2008-02-19 2009-02-18 Process for preparing a pharmaceutical formulation of contrast agents
CA2714118A CA2714118C (fr) 2008-02-19 2009-02-18 Procede de preparation d'une formulation pharmaceutique d'agents de contraste
KR1020107020477A KR101063060B1 (ko) 2008-02-19 2009-02-18 조영제의 약학적 제제를 제조하는 공정
PT97124036T PT2242515E (pt) 2008-02-19 2009-02-18 Processo para produzir uma formulação farmacêutica de agentes de contraste
ES09712403.6T ES2477541T3 (es) 2008-02-19 2009-02-18 Proceso para preparar una formulación farmacéutica de agentes de contraste
US13/971,672 US20130336898A1 (en) 2008-02-19 2013-08-20 Process for preparing a pharmaceutical formulation of contrast agents
JP2014015276A JP5985523B2 (ja) 2008-02-19 2014-01-30 造影剤の薬学的製剤を調製する方法
HRP20140537AT HRP20140537T1 (hr) 2008-02-19 2014-06-09 Postupak za pripravu farmaceutske formulacije kontrastnih sredstava
CY20141100489T CY1115259T1 (el) 2008-02-19 2014-07-01 Διαδικασια για την παρασκευη φαρμακοτεχνικης μορφης σκιαγραφικων παραγοντων
JP2016066978A JP6422460B2 (ja) 2008-02-19 2016-03-30 造影剤の薬学的製剤を調製する方法
US15/140,132 US20160235868A1 (en) 2008-02-19 2016-04-27 Process for preparing a pharmaceutical formulation of contrast agents
US15/140,077 US9636427B2 (en) 2008-02-19 2016-04-27 Process for preparing a pharmaceutical formulation of contrast agents
HRP20161312TT HRP20161312T2 (hr) 2008-02-19 2016-10-11 Postupak za pripravu farmaceutske formulacije kontrastnih sredstava
CY20161101126T CY1118985T1 (el) 2008-02-19 2016-11-03 Διαδικασια για την παρασκευη φαρμακοτεχνικης μορφης σκιαγραφικων παραγοντωn
US15/466,600 US9907866B2 (en) 2008-02-19 2017-03-22 Process for preparing a pharmaceutical formulation of contrast agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0851055A FR2927539B1 (fr) 2008-02-19 2008-02-19 Procede de preparation d'une formulation pharmaceutique d'agents de contraste.

Publications (2)

Publication Number Publication Date
FR2927539A1 FR2927539A1 (fr) 2009-08-21
FR2927539B1 true FR2927539B1 (fr) 2010-07-30

Family

ID=39789784

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0851055A Expired - Fee Related FR2927539B1 (fr) 2008-02-19 2008-02-19 Procede de preparation d'une formulation pharmaceutique d'agents de contraste.

Country Status (1)

Country Link
FR (1) FR2927539B1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2945448B1 (fr) 2009-05-13 2012-08-31 Guerbet Sa Procede de preparation d'une formulation pharmaceutique de chelate de lanthanide sous forme de poudre.
EP2786768A1 (fr) * 2013-04-04 2014-10-08 Agfa Healthcare Procédé de préparation d'un matériau comprenant un ligand macrocyclique et de production d'une formulation pharmaceutique comprenant ledit ligand avec un lanthanide
DK2988756T4 (da) * 2013-04-26 2022-08-08 Guerbet Sa Formulering af kontraststof og dertil knyttet fremstillingsfremgangsmåde
EP3789044A1 (fr) * 2016-10-28 2021-03-10 B.E. Imaging GmbH Procede de fabrication de compositions pharmaceutiques comprenant des chélates de gadolinium ayant des contaminations toxiques réduites
US20190269805A1 (en) 2016-12-29 2019-09-05 Inventure, LLC Solvent-free gadolinium contrast agents
CN110114093A (zh) * 2016-12-29 2019-08-09 创意有限责任公司 无溶剂钆造影剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3640708C2 (de) * 1986-11-28 1995-05-18 Schering Ag Verbesserte metallhaltige Pharmazeutika
DE3854717T3 (de) * 1987-06-30 1999-04-15 Mallinckrodt, Inc. (N.D.Ges.Des Staates Delaware), St. Louis, Mo. Verfahren zur erhöhung der sicherheit von metall-ligandchelaten als röntgenstrahlen-kontrastmittel.
US20100098640A1 (en) * 2005-06-20 2010-04-22 Cohen Seth M Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
WO2007121453A2 (fr) * 2006-04-17 2007-10-25 The Regents Of The University Of California Agents chélateurs de 2-hydroxy-1-oxo-1,2-dihydro-isoquinoline

Also Published As

Publication number Publication date
FR2927539A1 (fr) 2009-08-21

Similar Documents

Publication Publication Date Title
HRP20161312T1 (hr) Postupak za pripravu farmaceutske formulacije kontrastnih sredstava
FR2947186B1 (fr) Procede de preparation d'une emulsion huile-dans-eau stable
FR2959742B1 (fr) Procede de preparation d'amino-acides ou esters satures comprenant une etape de metathese
FR2906252B1 (fr) Procede de preparation d'halogenures de n-aklyl naltrexone
WO2010134047A3 (fr) Formes posologiques liquides d'isotrétinoïne
FR2918990B1 (fr) Procede de preparation de compositions pulverulentes stables
FR2962731B1 (fr) Procede de preparation de derives d'amino-benzoyl-benzofurane
FR2958291B1 (fr) Procede de preparation de derives d'amino-benzofurane
FR2927539B1 (fr) Procede de preparation d'une formulation pharmaceutique d'agents de contraste.
FR2914636B1 (fr) Procede de preparation d'une zeolithe beta
FR2952630B1 (fr) Procede de preparation d'une solution comprenant de la monochloramine
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
FR2939795B1 (fr) Procede de preparation d'esters actives
FR2945448B1 (fr) Procede de preparation d'une formulation pharmaceutique de chelate de lanthanide sous forme de poudre.
IL192190A0 (en) Process for the preparation of pharmaceutical salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid
FR2924115B1 (fr) Procede de preparation d'un acide trifluoromethanesulfinique
FR2947265B1 (fr) Procede de preparation d'alkylalcanolamines
FR2927900B1 (fr) Procede de preparation d'alpha-aminoacetals optiquement actifs.
HUP0700756A2 (en) Process for the preparation of pharmaceutical intermediers
FR2890959B1 (fr) Procede de preparation d'une composition de platre.
FR2940086B1 (fr) Formulation pharmaceutique de fenofibrate nanonise
FR2936790B1 (fr) Procede de preparation d'une zeolithe de type structural mtw
FR2909671B1 (fr) Procede de preparation de composes 1,3,2-oxazaborolidines
FR2929947B1 (fr) Procede de preparation d'une composition photoreticulable.
BR112013007904A2 (pt) "composto, composição farmacêutica, medicamento, uso de um composto e proceso para preparar um composto"

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 9

LIMR Limitation of claims

Effective date: 20160518

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

ST Notification of lapse

Effective date: 20231005